MorphoSys AG : MorphoSys to Host Conference Call on Strategic Alliance with Celgene to Advance CD38 Cancer Program MOR202 for
MorphoSys AG : MorphoSys to Host Conference Call on Strategic Alliance with Celgene to Advance CD38 Cancer Program MOR202 for Patients with Multiple Myeloma
MARTINSRIED, GERMANY and MUNCHEN, GERMANY -- (Marketwired) -- 06/27/13 -- MorphoSys AG / MorphoSys AG : MorphoSys to Host Conference Call on Strategic Alliance with Celgene to Advance CD38 Cancer Program MOR202 for Patients with Multiple Myeloma. Ad hoc announcement according to Section 15 WpHG. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
On June 26, 2013, MorphoSys and Celgene Corporation announced an agreement to jointly develop MOR202 globally and to co-promote MOR202 in Europe. MOR202 is a fully human monoclonal antibody targeting CD38 to treat patients with multiple myeloma (MM) and certain leukemias.
Today at 4:00 p.m. CET (10:00am EST, 03:00pm BST), the Management Board of MorphoSys AG will host a public conference call and webcast to present more information on the transaction.
Dial-in number for the Conference Call (listen-only):
Germany: +49 89 2444 32975
For U.K. residents: +44 20 3003 2666
For U.S. residents: +1 202 204 1514
MorphoSys offers participants the opportunity to follow the presentation through a simultaneous slide presentation online at http://www.morphosys.com.
An audio replay and manuscripts of the conference will be available on www.morphosys.com/conference-calls in due course.
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http: //www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R) and 100 billion high potentials(R) are registered trademarks of MorphoSys AG.
Slonomics(R) is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
Conference Call Alert (PDF):
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
For more information, please contact:
MorphoSys AG Dr. Claudia Gutjahr-Loser Head of Corporate Communications & IR Tel: +49 (0) 89 / 899 27-122
Mario Brkulj Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-454
Alexandra Goller Specialist Corporate Communications & IR Tel: +49 (0) 89 / 899 27-332